Q4 2024 Earnings Call Transcript March 12, 2025 biote Corp. beats earnings expectations. Reported EPS is $0.1, expectations ...

Corp. (BTMD) delivered earnings and revenue surprises of 11.11% and 2.85%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

These updates follow the latest evidence-based medical literature and feature proprietary dosing algorithms that are unique in the marketplace. With these new algorithms, Biote-certified ...

personalized hormone optimization and therapeutic wellness solutions delivered by Biote-certified medical providers. Biote trains practitioners to identify and treat early indicators of aging ...

Contineum Therapeutics, Inc. (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology ...

Truist Financial analyst Les Sulewski maintained a Buy rating on biote (BTMD – Research Report) today and set a price target of $7.00. The company’s shares closed yesterday at $4.10.

Reports Q4 revenue $49.8M, consensus $51.2M. “In 2024 Biote (BTMD) strengthened its capabilities to provide the next level of individualized and evidence-based healthcare,” said Bob Peterson ...

Good day and welcome to the Biote fourth quarter 2024 earnings conference call. (Operator Instructions) Please note that this event is being recorded. I would now like to turn the conference over to ...